New hope for tough cancers: first patients test novel drug AB521
NCT ID NCT05536141
Summary
This is the first study in people to test a new drug called AB521 (casdatifan). The main goal is to find safe doses and see how the body processes the drug. It will be tested alone and in combinations for people with advanced kidney cancer and other solid tumors that have not responded to other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, South Korea
-
Ashford Cancer Centre Research/ICON
RECRUITINGSydney, Australia
-
Barbara Ann Karmanos Cancer Center
RECRUITINGDetroit, Michigan, 48201, United States
-
Box Hill Hospital
NOT_YET_RECRUITINGMelbourne, Australia
-
Chris O'Brien Lifehouse
NOT_YET_RECRUITINGCamperdown, Australia
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322-1013, United States
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Macquarie University Hospital
RECRUITINGSydney, Australia
-
Memorial Sloan Kettering
RECRUITINGNew York, New York, 10065, United States
-
Nebraska Cancer Specialists - Oncology Hematology West PC
RECRUITINGOmaha, Nebraska, 68124, United States
-
Oschner Health
RECRUITINGNew Orleans, Louisiana, 70121, United States
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
-
Sarah Cannon
RECRUITINGNashville, Tennessee, 37203, United States
-
Seoul National University Bundang Hospital
RECRUITINGSeoul, South Korea
-
Severance Hospital
RECRUITINGSeoul, South Korea
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
-
South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
-
Tisch Cancer Institute, Icahn Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University Hospitals Cleveland Clinical
RECRUITINGCleveland, Ohio, 44106, United States
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
-
University of California at San Diego
RECRUITINGSan Diego, California, 92093, United States
-
University of Louisville Brown Cancer Center
RECRUITINGLouisville, Kentucky, 40202, United States
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
-
Vall d'Hebron Institute of Oncology (VHIO)
NOT_YET_RECRUITINGBarcelona, Spain
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37240, United States
Conditions
Explore the condition pages connected to this study.